Browse

F2G and Shionogi announced that their joint antifungal candidate, olorofim, met the primary endpoints in a Phase 3 trial. The data were released Thursday morning and showed the drug performed compa…

Kardigan, a cardiovascular drug startup, priced a $400 million initial public offering on Wednesday, adding to a recent surge in large biotech offerings. The company becomes the fourth biotech in…